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Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an
effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer
types. Anti-PD-1 and anti-PD-L1 antibodies have resulted in long-term responses with minimal side effects in significant numbers
of patients with melanoma, lung, kidney, bladder and triple-negative breast cancer, as well as in chemotherapy-refractory Hodgkin
disease. There is already evidence from at least one randomised trial that anti-PD-1 therapy is superior to chemotherapy in the
treatment of patients with metastatic melanoma, and two anti-PD-1 antibodies, pembrolizumab and nivolumab, have been
approved by the US Food and Drug Administration for the treatment of patients previously treated for metastatic melanoma. It is
anticipated that approvals by drug regulatory bodies will be forthcoming in several cancers in the next months.
Blockade of cytotoxic T-lymphocyte antigen-4 (CTLA-4) and
programmed cell death protein-1 or its ligand (PD-1/L1) represent
a paradigm shift in immunotherapy for cancer, as it focus on the
disinhibition of native immune responses instead of the prior focus
in activation of the immune system with tumour vaccines or
recombinant cytokines. Among the most promising approaches to
activating therapeutic antitumour immunity is the blockade of
immune checkpoints. CTLA-4 was the first negative regulatory
checkpoint receptor to be clinically targeted. CTLA-4 is upregu-
lated early during the T-cell activation and its expression dampens
T cells by outcompeting CD28 in binding CD80 and CD86 (Linsley
et al, 1994; Egen and Allison, 2002; Riley et al, 2002). Antibodies
that block CTLA-4 enhance immune responses by activating
effector T cells, but probably also by interacting with other
immune cells such as regulatory T cells (Tregs), which exhibit
immunosuppressive properties (Lenschow et al, 1996; Wing et al,
2008). The anti-CTLA-4 antibody ipilimumab (Yervoy; Bristol-
Myers Squibb, Princeton, NJ, USA) showed a significant overall
survival (OS) improvement in patients with advanced melanoma in
two randomised phase III trials (Hodi et al, 2010; Robert et al,
2011), and was approved by the US Food and Drug Administration
(FDA) and other drug regulatory bodies in 2011. The broad
activation of the immune system and deregulation of an
immunologic homoeostasis achieved by blocking CTLA-4 might
be responsible for the development of inflammatory or auto-
immune toxicities, reported in B15% of the patients (Robinson
et al, 2004).
In contrast, PD-1 appears to have a prominent role in
modulating T-cell activity in peripheral tissues via interaction
with its ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC). Programmed
cell death protein-1 is an immune checkpoint receptor that
prevents overstimulation of immune responses and contributes to
the maintenance of immune tolerance to self-antigens (Freeman
et al, 2000; Keir et al, 2006; Korman et al, 2006; Okazaki and
Honjo, 2007). Upon antigen recognition, activated T cells express
PD-1 on their surface and produce interferons that lead to the
expression of PD-L1 in multiple tissues, including cancer (Ishida
et al, 1992; Pardoll, 2012). Binding of PD-1 to its ligands limits
effector T-cell activity, and therefore regulating detrimental
immune responses and preventing autoimmunity (Topalian et al,
2012a). Programmed cell death protein-1 is not only induced on
effector T cells but also on Tregs (Francisco et al, 2009), activated B
cells and natural killer cells (Terme et al, 2011), suggesting its
contribution to other important immune cell functions.
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Besides the interaction between CTLA-4 and PD-1 with their
respective ligands, other costimulatory and inhibitory interactions
regulate T-cell responses. Although not the focus of the current
review, examples of promising inhibitors of immune checkpoint
targets that are being pursued clinically using blocking antibodies
include the lymphocyte-activation gene 3, the T-cell membrane
protein 3 or the adenosine receptor A2aR.
REGULATION OF EXPRESSION OF PD-1 AND ITS
LIGANDS
For PD-1 to inhibit effector T-cell function, engagement to its
ligands is needed. Peripheral tissues that are able to express PD-L1
constitutively or upon interferon exposure include both haemato-
poietic and non-haematopoietic tissues. Numerous tumour types
are also able to express PD-L1 (Zou and Chen, 2008), including
urothelial, ovarian, breast, cervical, colorectal, pancreatic, gastric
cancer, melanoma, glioblastoma and non-small-cell lung cancer
(NSCLC), suggesting that the pathway may be involved in immune
evasion by many different human cancers. Less is known about
PD-L2, which is expressed on dendritic cells, macrophages, mast
cells and B cells (Topalian et al, 2012b). In tumours, PD-L2 is
upregulated on primary mediastinal B-cell lymphoma, follicular
B-cell lymphoma and Hodgkin lymphoma (Rosenwald et al, 2003).
An important consideration is the mechanism that contributes
to PD-L1 expression in the surface of tumour cells. Tumour PD-L1
membrane expression can be constitutive through oncogenic
processes (Parsa et al, 2007; Pardoll, 2012) or induced by activated
tumour antigen-specific T cells that produce interferons (Taube
et al, 2012). Thus, the expression of PD-L1 can be considered a
dynamic process during effector T-cell antigen recognition.
Recent data suggest that inducible PD-L1 expression may be
most important for responses to PD-1 blockade therapy. In this
scenario, the pre-existing presence of PD-1-positive T cells with
tumour antigen specificity, which became inactivated upon PD-L1
engagement, is required for antitumour responses. This critical
mechanism has been termed acquired immune resistance (Pardoll,
2012), and differs from other possible scenarios where tumour cells
express PD-L1 in the absence of effector T cells or effector T cells
are present but not properly activated and therefore not able to
express PD-1 (Ribas and Tumeh, 2014).
Tumour infiltration with effector T cells and PD-L1 expression
have been associated with objective responses to the anti-PD1
antibody pembrolizumab in biopsies of patients with advanced
melanoma (Tumeh et al, 2014). A more clonal TCR receptor
repertoire in the previous patients with clinical benefit has also
been observed. Other work focused on inducible PD-L1 expressed
by tumour-infiltrating T cells as predictive of response, which is
also likely a reflection of the presence of tumour antigen-specific
T cell-producing interferons. Although these findings strongly
reinforce the concept of acquired immune resistance within the
tumour, patients with PD-L1-non-expressing tumours could also
potentially benefit from these agents, considering the previously
described plasticity of the tumour with the upregulation of PD-L1,
the heterogeneity of its expression levels (Taube et al, 2012) and
the number of clinical reports where patients with both PD-L1-
positive and -negative baseline tumour biopsies were associated
with clinical benefit, although the latest group with less objective
responses (Hodi et al, 2014; Kefford et al, 2014).
Programmed cell death protein-1/ligand-1 has also been studied
as a prognostic biomarker in many different primary tumours, with
equivocal results (Rosenwald et al, 2003; Parsa et al, 2007; Hino
et al, 2010). Variations in cancer type, stage of cancer analysed,
PD-L1 monoclonal antibody used for IHC staining, laboratory
techniques for IHC staining and treatment history may have
contributed to the diverse results.
TARGETING THE PD-1 PATHWAY
Several antibodies that inhibit the PD-1 pathway by blocking either
PD-1 or PD-L1 are being developed for clinical use in a variety of
tumour types and clinical settings (Table 1). These agents differ in
structure and are generally classified into two groups: anti-PD1 and
anti-PD-L1 antibodies. Antibodies that inhibit PD-1 block its
binding to both PD-L1 and PD-L2, whereas anti-PD-L1 antibodies
only block the PD-1:PD-L1 interaction and potentially the PD-
1:CD80 interaction. Whether this difference affects clinical activity,
organ-specific immune modulation or toxicity needs to be
elucidated.
Regarding the anti-PD-1 antibodies, the fully human nivolumab
(Bristol-Myers Squibb) and the humanised pembrolizumab
(Merck, Whitehouse Station, NJ, USA) are IgG4 monoclonal
antibodies that block the binding of PD-1 receptor to PD-L1 and
PD-L2. Pembrolizumab has an optimised fragment crystallisable
(fc) region that minimises antibody-dependent cell-mediated
cytotoxicity (ADCC) and complement-dependent cytotoxicity
(CDC). In contrast, the third anti-PD-1 antibody with more
extensive clinical development pidilizumab (CureTech, Yavne,
Israel) is an IgG1 antibody, which confers more ADCC and CDC.
Antibodies in clinical development that target PD-L1 include
MPDL3280A (Genentech, South San Francisco, CA, USA),
MEDI4736 (MedImmune/AstraZeneca) and MSB0010718C
(EMD Serono, Rockland, MA, USA), all of them IgG1 isotype.
MPDL3280A and MEDI4736 have genetically modified Fc
fragments to avoid ADCC, which is of particular importance for
anti-PD-L1 antibodies as activated T cells readily express PD-L1
(Herbst et al, 2014). No data are available regarding the
comparison of these agents and we will focus on describing the
clinical data available for these antibodies in different tumours.
Table 1. Anti-PD-1/L-1 agents in clinical development
Agents Prior names Manufacturer IgG type Affinity
Nivolumab MDX1106, BMS936558 BMS-ONO IgG4 fully human AB 3 nM
Pembrolizumab Lambrolizumab
MK-3475
Merck IgG4 engineered humanised AB o100pM
Pidilizumab CT-011 CureTech IgG1k humanised AB –
BMS936559 MDX1105 BMS-ONO IgG4 fully human AB –
MPDL3280A RG7446 Genentech/Roche IgG1 engineered fully human AB –
MEDI4736 MedImmune IgG1 engineered fully human AB –
MSB0010718C Merck Serono IgG1 fully human AB –
Abbreviations: AB¼ antibody; IgG¼ immunoglobulin G; PD-1/L-1¼programmed cell death protein-1 or its ligand.
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PD-1 BLOCKADE EFFICACY: FIRST EVIDENCE OF
CLINICAL ACTIVITY
The most extensive clinical experience with PD-1 antibodies has
been obtained with both nivolumab and pembrolizumab, which
have demonstrated highly durable response rates with acceptable
toxicity in large phase I studies involving patients with advanced
melanoma, NSCLC, renal cell carcinoma (RCC) and Hodgkin’s
disease, among others (Topalian et al, 2012b, 2014; Hamid et al,
2013a; Ansell et al, 2015).
Nivolumab was first evaluated in a phase I/II study in 296
patients with a variety of heavily pretreated malignancies including
melanoma, NSCLC, prostate cancer, RCC and colorectal cancer.
Patients received nivolumab at doses of 1–10mg kg 1 of body
weight every 2 weeks for up to 12 cycles until disease progression
or a complete response occurred. No maximum-tolerated dose
(MTD) was defined and only 14% of the patient experienced grade
3/4 drug-related adverse events. Cumulative response rates (all
doses) were 18.4% (14 out of 76) among patients with NSCLC,
27.6% (26 out of 94) among patients with melanoma and 27.3%
(9 out of 33) among patients with RCC (Topalian et al, 2012b).
These results generated enthusiasm among oncologists and
provided evidence of clinical activity in neoplasms classically
considered non-immunogenic.
In parallel to the clinical development of nivolumab, the anti-
PD-1 antibody pembrolizumab was similarly showing impressive
tumour responses in a more restricted population of patients with
advanced melanoma (Hamid et al, 2013a). Hamid et al (2013a)
reported 135 patients with advanced melanoma being treated with
three separate dosing strategies: 10mg kg 1 of body weight every 2
or 3 weeks or 2mg kg 1 every 3 weeks. Some patients were
previously treated with ipilimumab. Adverse events were similar to
those found in patients treated with nivolumab, including fatigue,
rash, pruritus and diarrhoea. Response rates across all dose levels
were 38%, with patients on the highest dose of pembrolizumab
showing a response rate of 52%. Responses were durable, and the
median progression-free survival (PFS) was longer than 7 months.
A subsequent prospective, randomised analysis was performed
using both 2 and 10mg kg 1 doses given every 3 weeks to patients
with ipilimumab-refractory advanced melanoma. The response
rate was 26% at both doses and the safety profile was similar,
making 2mg kg 1 once every 3 weeks the recommended dose for
further studies (Robert et al, 2014). An updated report on the
phase I clinical trial (KEYNOTE-001) included the analysis of 411
melanoma patients treated across multiple dose levels. Median OS
data was not available, but 1-year OS rate over all dose cohorts was
69% (Ribas et al, 2014a).
Pidilizumab has been more predominantly evaluated in
haematologic malignancies. A phase I dose-escalating trial tested
pidilizumab in 17 patients with refractory acute myeloid
leukaemia, chronic lymphocytic leukaemia, Hodgkin and non-
Hodgkin lymphoma or multiple myeloma and reported an
acceptable safety profile, with no MTD defined and clinical benefit
in 33% of the patients evaluated (Berger et al, 2008).
Targeting PD-L1 is a similarly promising approach to targeting
PD-1. BMS-956559, although no longer under clinical develop-
ment, was the first PD-L1 antibody to show durable tumour
regressions in patients with a variety of solid tumours, mostly
NSCLC and melanoma, and also RCC, colorectal, ovarian,
pancreatic, gastric and breast cancer (Brahmer et al, 2012).
Other anti-PD-L1 antibodies such as MPDL3280A, MEDI4736
and MSB0010718C have also shown responses in early-phase
clinical trials in a number of malignancies (Herbst et al, 2013;
Heery et al, 2014; Segal et al, 2014). MPDL3280A phase I testing in
patients with multiple histologies was well tolerated and did not
reach a MTD (Herbst et al, 2013). Pharmacokinetic data supported
dosing at 15mg kg 1 every 3 weeks and activity was observed in
multiple tumour types including NSCLC, RCC, melanoma, color-
ectal and gastric cancer. In phase I, another anti-PD-L1 antibody,
MEDI4736, exhibited dose-dependent pharmacokinetics and
yielded dose-dependent PD-L1 suppression (Fairman et al,
2014), with an acceptable safety profile, no MTD and evidence
of clinical activity across multiple cancer types including
melanoma, gastro-oesophageal, pancreatic cancer and head and
neck squamous cell carcinoma (Segal et al, 2014). MSB0010718C
dose-escalation trial was performed and investigators demon-
strated that MSB0010718C could be safely administered in doses
up to 20mg kg 1 2 weeks. Further development of this antibody is
planned in patients with metastatic or locally advanced solid
tumours. A summary of the phase II/III relevant clinical data for
each agent is included in Table 2 and detailed below.
PD-1/L1 BLOCKADE IN DIFFERENT TUMOURS
Melanoma. Nivolumab was recently compared with dacarbazine
in a phase III randomised double blind study in patients with
treatment-naive BRAF wild-type advanced melanoma (n¼ 418)
(Robert et al, 2014). The median OS was not reached for
nivolumab vs 10.8 months for dacarbazine and 1-year survival
rate was 73% vs 42%, respectively. This survival advantage was
observed in both PD-L1-positive and -negative nivolumab-treated
patients. Drug-related adverse events were more common in the
dacarbazine-treated group. In a separate phase III trial, nivolumab
was compared with investigator’s choice chemotherapy in patients
who had experienced progression on ipilimumab and resulted in
an increased overall response rate from 11% to 32%, with less
frequent high-grade adverse events (Weber et al, 2014). Nivolumab
was approved in December 2014 for patients with advanced
melanoma after disease progression to a previous therapy.
Table 2. Anti-PD-1/L1 agents: clinical data from phase II/III clinical trials
Anti-PD-1/L1 Phase Pts ORR Disease Grade3–4 AE
Median
PFS (Mo) 1-year OS Reference
Nivolumab 2 168 20 RCC 17 4.2 (10mg kg1) NR Motzer et al (2014b)
Nivolumab 2 117 15 NSCLC 17.1 41
Nivolumab 3 418 40 MM 11.7 5.1 NR Robert et al (2014)
Nivolumab 3 268 32 MM 9 NR NR Weber et al (2014)
Pembrolizumab 2 540 21 (2mg kg 1)
25 (10mg kg 1)
MM ipi refractory 11 (2mgkg 1)
14 (10mg kg 1)
2.9 (2mg kg1)
2.9 (10mg kg1)
NR Ribas et al (2014b)
Pidilizumab 2 103 5.9 MM 2.8 64.5 Atkins et al (2014)
PidilizumabþRituximab 2 30 66 FL 0 21.1 NR Westin et al (2010)
Abbreviations: AE¼ adverse events (%); MM¼metastatic melanoma; NR¼ not reported; NSCLC¼ non-small-cell lung cancer; ORR¼overall response rate (%); PD-1/L-1¼programmed cell
death protein-1 or its ligand; PFS¼progression-free survival (months); Pts¼patients; RCC¼ renal cell carcinoma; 1-year OS¼ years overall survival (%).
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Phase II randomised clinical data with pembrolizumab have also
been recently reported. At the 2014 Society for Melanoma Research
(SMR) meeting, results on the primary end point of PFS comparing
two dosing regimens of pembrolizumab with chemotherapy in
patients with ipilimumab-refractory advanced melanoma were
presented (Ribas et al, 2014b). Pembrolizumab provided significant
improvements in PFS and durable objective responses while better
preserving health-related quality of life compared with chemotherapy.
Pembrolizumab received FDA approval in September 2014 for
patients with melanoma previously treated with ipilimumab and, if
BRAF V600 mutation positive, a BRAF inhibitor.
Expansion cohorts of patients with metastatic melanoma treated
with MPDL3280A resulted in an overall response rate of 26%
(9 out of 35) and a 24-week PFS of 35% (Hamid et al, 2013b).
MPDL3280A is currently being explored in combination with
vemurafenib in advanced BRAF-mutated melanoma. The anti-PD-
L1 antibody MEDI4736 is also currently under investigation in
combination with dabrafenib and trametinib, or with trametinib
alone, in subjects with metastatic melanoma with or without BRAF
mutations, respectively.
Targeting T-cell activation at different stages of the immune
response might lead to an increased efficacy in the clinical setting,
while potentially delaying resistance to either agent. Combining the
blockade of PD-1 and CTLA-4 in preclinical models achieved a
more pronounced antitumour activity than blockade of either
pathway alone and provided the rationale for further studying this
combination (Curran et al, 2010). A phase I study evaluated the
safety and efficacy of a concurrent regimen of ipilimumab and
nivolumab in patients with advanced melanoma (Wolchok et al,
2013). Concurrent treatment was associated with an overall
response rate of 40%, which seemingly exceeded the previously
reported results with either agent alone (Hodi et al, 2010; Topalian
et al, 2012b). However, 53% of the patients treated with the
concurrent regimen had grade 3/4 treatment-related adverse
events, which is higher than the previous rates among patients
treated with ipilimumab or nivolumab alone. Whether the
antitumour effect of both agents is more active than either agent
alone is being addressed in a phase III clinical trial and results are
eagerly awaited.
Non-small-cell lung carcinoma. Non-small-cell lung carcinoma is
one great example of a cancer type that was not believed to be
immune-responsive and where antibodies blocking the PD-1
checkpoint have shown therapeutic activity. Similar to melanoma,
expression of immunoinhibitory molecules in the tumour micro-
environment appears to be a relevant mechanism for immune
resistance in NSCLC. Both PD-L1 and PD-L2 have been reported
to be upregulated in NSCLC (Zou and Chen, 2008; Pardoll, 2012).
Downregulation of components of the antigen-presenting machin-
ery, particularly among smoking-associated lung cancer patients
(Pleasance et al, 2010), appears to be another important immune
resistance mechanism.
The initial signs of anti-PD-1 activity in patients with NSCLC
were reported in the dose-escalation phase I clinical trial that
evaluated nivolumab in different solid tumours (Topalian et al,
2012b). Expansion cohorts of patients with NSCLC showed
significant responses and disease stabilisation in both non-
squamous and squamous lung carcinoma. Durability of clinical
responses, unique to immunotherapy, was unprecedented (median
duration of response was 74 weeks and 1- and 2-year OS was 42%
and 14%, respectively) (Brahmer et al, 2013). Of note, eight
patients developed pneumonitis, three of which were grade 3/4.
This organ-specific immune toxicity might be of particular
importance in patients with NSCLC, as these patients may harbor
some degree of pulmonary inflammation that might be enhanced
upon PD-1 blockade.
Taken together, these encouraging results have led to the
development of nivolumab in two separate phase III clinical trials.
As a single agent, nivolumab is being compared with docetaxel in
patients with non-squamous histology in the second- or third-line
treatment setting and in patients with squamous cell histology after
one prior platinum-containing regimen. In addition to multiple
treatment-arm phase I trials where this antibody is being combined
with various chemotherapy regimens, nivolumab is also being
explored in the neoadjuvant setting in resectable NSCLC.
Regarding the testing of pembrolizumab in this patient
population, a phase I clinical trial of previously treated patients
with locally advanced or metastatic NSCLC was also recently
reported. Enrolled patients had PD-L1 detected in their tumours by
an immunohistochemical assay, although some patients with
tumours without PD-L1 expression who had received at least
two prior lines of therapy were also included. Treatment was
generally well tolerated, although three patients experienced grade
3/4 drug-related pneumonitis. Robust antitumour activity was
observed with a preliminary higher response rate (24%) for
patients with PD-L1-positive tumours compared with PD-L1-non-
expressing tumours (8%) (Garon et al, 2014).
Blocking anti-PD-L1 is a strategy extensively being evaluated in
patients with NSCLC. MPDL3280A expansion cohort for pre-
viously treated patients with metastatic NSCLC observed an overall
response rate of 24% (9 out of 37) in patients with both squamous
and non-squamous histology, including several patients with rapid
tumour shrinkage and additional patients with delayed responses
after apparent radiographic progression (Spigel et al, 2013). There
were no cases of grade 3/4 pneumonitis, suggesting a potentially
more tolerable safety profile with anti-PD-L1 inhibitors in patients
with NSCLC. Ongoing trials include a single-arm phase II study of
MPDL3280A in chemonaive and prior platinum-based treated
patients with PD-L1-positive tumours and a phase III efficacy and
safety evaluation of MPDL3280A compared with docetaxel after
failure of a platinum-containing chemotherapy regimen.
Preliminary clinical activity with MEDI4736 in patients with
NSCLC has also been observed, with three partial responses and
two additional patients showing tumour shrinkage not meeting
partial response out of 13 patients evaluated (Brahmer et al, 2014).
Same as with MPDL3280A, safety was acceptable and no grade 3/4
pneumonitis was observed. Several large combination trials are
ongoing including the combination of an anti-EGFR and
MEDI4736 in advanced NSCLC, its sequential administration
after concurrent chemoradiation in stage III or vs placebo after a
complete resection.
Renal cell carcinoma. Immunomodulation has classically been
considered a therapeutic strategy for RCC, and cytokine-based
immunotherapeutic agents such as IL-2 are associated with modest
rates of highly durable responses. PD-L1 is increased in
inflammatory conditions of the kidney and in RCC, as opposed
to normal renal tissue, suggesting its role in negatively regulating
T-cell function (Ding et al, 2005).
A randomised phase II clinical trial evaluated different doses of the
nivolumab in patients with advanced RCC and observed long-lasting
objective responses in 20–22% of the patients evaluated across all
groups. Median OS was 18.2 months for the 0.3mgkg 1 dose and
was not reached for the 2 or 10mgkg 1 doses (Motzer et al, 2014a).
Results from a phase III study comparing nivolumab to everolimus in
pretreated metastatic RCC could potentially lead to the registration of
the anti-PD-1 antibody in this therapeutic setting. Nivolumab is
currently being developed in combination with either sunitinib or
pazopanib, with promising results in terms of efficacy but high level of
toxicity (Amin et al, 2014). In the same trial, two separate arms
evaluated the combination of ipilimumab plus nivolumab, with
preliminary results suggesting the synergy of the combination, at the
expense of significant toxicity (Hammers et al, 2014).
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Pembrolizumab is currently being investigated in a phase I/II
trial in combination with pazopanib in treatment-naive patients
with metastatic RCC. Once the recommended phase II dose is
determined, the potential for synergy combining both agents will
be evaluated. Other antiangiogenics combined with pembrolizu-
mab include axitinib.
The initial experience with MPDL3280A in RCC indicated the
presence of responses across all dose, with some patients with RCC
experiencing prolonged stable disease before experiencing tumour
response. The 24-week PFS was 50% among the 39 patients
evaluated for efficacy (Cho et al, 2013). MPDL3280A is currently
being investigated as monotherapy or in combination with
bevacizumab as compared with a control arm of sunitinib in
patients with treatment-naive, locally advanced or metastatic RCC.
Triple-negative breast cancer. Programmed cell death protein-1/
ligand-1 is expressed in 20% of triple-negative breast cancer
(TNBCs), suggesting PD-L1 as a therapeutic target in TNBCs
(Mittendorf et al, 2014). A phase Ib clinical trial with pembroli-
zumab in 27 patients with heavily pretreated recurrent or
metastatic TNBC positive for PD-L1 achieved one complete
response, four partial responses and seven cases with stable
disease. Another complete response and two partial responses were
obtained in a similar subgroup of patients with MPDL3280A.
Bladder cancer. A clinical trial involving patients with heavily
pretreated metastatic bladder cancer selected to be PD-L1-positive
based on an analysis of the PD-L1 expression on immune-
infiltrating cells resulted in 10 out of 20 with a response (9 partial
responses and 1 complete response). Response rates for patients
with PD-L1-negative tumours have yet to be published (Powles
et al, 2014). This study had a short follow-up of just 2.8 months,
and further information will be needed to assess the benefits of PD-
1/L1 blockade in patients with bladder cancer.
Haematologic malignancies. The importance of the PD-1 axis in
leukaemias and lymphomas has been demonstrated in several
different scenarios. Examples of haematologic malignancies that
frequently express PD-L1 include adult T-cell leukaemia lym-
phoma (Kozako et al, 2009), angioimmunoblastic T-cell lymphoma
(Xerri et al, 2008), (Wilcox et al, 2009) and non-Hodgkin
lymphoma (Andorsky et al, 2011), among others.
Phase II clinical trial combining pidilizumab and rituximab in
patients with relapsed follicular lymphoma demonstrated an
overall response rate of 66%, with 52% of participants achieving
a complete response. No grade 3/4 side effects were observed
(Westin et al, 2010). Patients with heavily pretreated relapsing or
refractory classic Hodgkin lymphoma were recently included as an
independent cohort in a dose escalation and cohort expansion
phase I study of nivolumab (Armand et al, 2014). With an
objective response rate as high as 87% (20 out of 23) including 17%
complete responses and a PFS rate at 24 weeks of 86%, a phase II
trial of nivolumab in this subset of patients is already underway.
Patients with relapsed or refractory classical Hodgkin
lymphoma were evaluated as a cohort of the ongoing multicentre,
open-label, phase Ib clinical trial of pembrolizumab in haemato-
logic malignancies and patients were treated with single-
agent pembrolizumab 10mg kg 1 administered intravenously
every 2 weeks. Twenty per cent of the 15 evaluable patients had
a CR at 12 weeks. Additionally, 33% had partial remission as best
overall response, for an overall response rate of 53% (Moskowitz
et al, 2014).
CONCLUSION
Anti-PD-1/L-1 antibodies are revitalising interest in solid tumour
immunotherapy after demonstrating impressive rates of clinical
benefit in patients with different neoplasms, some of them
classically not considered immunoresponsive. We are starting to
understand which patients are more likely to benefit from anti-PD-
1/L1-blocking strategies, and the potential for biomarkers asso-
ciated with response will ultimately lead to improved patient care.
Because of the complexity of the tumour environment, the high
number of cells and molecules implicated in tumour immune
evasion and therefore potential therapeutic targets, further studies
might likely uncover additional immunologic checkpoints, which
can be targeted alone or in combination with other immunother-
apeutic approaches. Such combinations will need to be developed
under a strong preclinical rational and taking into consideration
the differences in the development of immunotherapeutic agents
compared with classic anticancer agents.
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